Chapter 6 Prophylactic Treatment of Craniofacial Dysostosis

2015 ◽  
pp. 44-45
Keyword(s):  
Prophylactic Treatment ◽  
Craniofacial Dysostosis

Prophylactic Treatment Protocol against the Severity of COVID-19 Using Melatonin

2020 ◽  
Author(s):  
Nejib Charaa ◽  
Mohamed Chahed ◽  
Habib Ghedira ◽  
Riadh Daghfous
Keyword(s):  
Prophylactic Treatment ◽  
Treatment Protocol

Metapneumovirus humano: epidemiología y posibles tratamientos profilácticos

2020 ◽  
Vol 63 (3) ◽  
pp. 7-18
Author(s):  
Marcela Solís-Rodríguez ◽  
Ángel G. Alpuche-Solís ◽  
Rocío G. Tirado-Mendoza
Keyword(s):  
Antigenic Determinant ◽  
Prophylactic Treatment ◽  
Respiratory Infections ◽  
Rna Virus ◽  
The Elderly ◽  
Etiologic Agent ◽  
Host Immunity ◽  
Acute Respiratory Infections ◽  
Antiviral Peptides ◽  
Fusion Glycoprotein

In 2001 in the Netherlands, Human metapneumovirus (hMPV) was identified as a “new” etiologic agent causing acute respiratory infections in children younger than 5 years old; however, it has also been isolated in the elderly and immunocompromised people. This virus is considered the second etiological agent in acute diseases of the respiratory tract. Currently, the estimated cost of IRAs in our country is of 9,000USD per inpatient. hMPV is a member of the genus Metapneumovirus, family Pneumoviridae, and it belongs to the order Mononegavirales that is part of the negative single-stranded ribonucleic acid (RNA) virus, consisting of eight genes ordered: 3’-N-P-M-FM2-SH-G-L-5 ‘, and which encodes for 9 proteins. Of these proteins, the F fusion glycoprotein is highly conserved in the genus Metapneumovirus, and is the major antigenic determinant, and because an approved vaccine doesn’t exist, it has been used as a candidate epitope for the design of a vaccine that confers host immunity or as a therapeutic target in the creation of antiviral peptides that inhibit the fusion of the virus to its target cell and to avoid infection in subjects at high risk of contagion since there is currently none accepted by COFEPRIS as a prophylactic treatment against hMPV. Key words: hMPV; respiratory infections; epitopes; protein F;vaccines.

Prophylactic treatment of asthma

2002 ◽  
Vol 78 (8) ◽  
pp. 141-50 ◽  
Author(s):  
José Augusto Rubim de Moura ◽  
Jacques de Blic ◽  
Paulo A. M. Camargos
Keyword(s):  
Prophylactic Treatment

Prophylactic Treatment of Migraine with Femoxetine — A Randomized Comparison with Placebo

Cephalalgia ◽  
1985 ◽  
Vol 5 (3_suppl) ◽  
pp. 516-517 ◽  
Author(s):  
Marianne Orholm ◽  
Pierre le Fèvre Honoré ◽  
Ib Zeeberg
Keyword(s):  
Prophylactic Treatment
Sign in / Sign up

Export Citation Format

Share Document